V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220014980 | 220009600 | null | null | Disease modification (D) | 2014-10-10 | 2014-10-15 | ALEMTUZUMAB + FLUDARABINE | N | N | 220036542 | DACARBAZINE |
| 220014981 | 220015086 | null | 72.5 | Palliative (P) | 2014-02-14 | 2014-02-28 | BENDAMUSTINE + RITUXIMAB | null | null | 220036543 | MITOXANTRONE + TRETINOIN |
| 220014984 | 220009604 | 1.64 | 64.1 | Curative (C) | 2014-06-13 | 2014-09-19 | Alemtuzumab + Cyclophos TBI Allo | null | N | 220036557 | BUSULPHAN |
| 220014985 | 220015089 | 1.7 | 92 | Palliative (P) | 2015-10-03 | 2016-11-02 | CETUXIMAB + IRINOTECAN + MDG | N | N | 220036560 | CAPECITABINE + OXALIPLATIN |
| 220014986 | 220009605 | 1.82 | 94.2 | Palliative (P) | 2017-10-12 | 2017-10-12 | Ipilimumab | N | N | 220036563 | LENALIDOMIDE |
| 220014987 | 220009608 | 1.6 | 60 | Disease modification (D) | 2014-01-10 | 2014-01-12 | CAV | N | N | 220036563 | CAV |
| 220014988 | 220018228 | 1.62 | 70.8 | Curative (C) | 2018-03-20 | 2018-04-06 | Arsenic Triox + Tretinoin Ind W1-4 | N | N | 220036566 | CYCLOPHOSHAMIDE |
| 220014989 | 220018228 | 1.65 | 44.4 | Curative (C) | 2013-11-04 | 2013-11-22 | Ipilimumab | 2 | N | 220036566 | PEMBROLIZUMAB |
| 220014990 | 220009611 | 1.67 | null | Disease modification (D) | 2017-05-29 | 2017-05-30 | EEF or EOF | N | N | 220036577 | ETOPOSIDE |
| 220014991 | 220009611 | 1.77 | 96.1 | Disease modification (D) | 2015-02-26 | 2015-04-18 | EOX | N | N | 220036577 | CISPLATIN |
| 220014992 | 220009613 | 1.62 | 65.6 | Curative (C) | 2016-03-14 | 2016-03-15 | Bortezomib +/- Dexamethasone | null | null | 220036590 | IPILIMUMAB |
| 220014993 | 220009615 | 1.67 | 58.4 | Palliative (P) | 2015-11-26 | 2015-12-01 | MPT | 02 | null | 220036594 | IPILIMUMAB |
| 220014995 | 220009617 | null | 69.8 | Palliative (P) | 2013-04-26 | 2013-09-30 | FLUDARABINE | 02 | null | 220036606 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220014997 | 220009623 | 1.58 | 52.5 | Adjuvant (A) | 2015-10-02 | 2015-10-09 | Cisplatin + Etoposide (3 day) | N | N | 220036614 | PEMBROLIZUMAB |
| 220014998 | 220009627 | 1.75 | 90.5 | Palliative (P) | 2012-10-02 | 2012-10-10 | Sunitinib | N | N | 220036619 | AFATINIB |
| 220014999 | 220009628 | 1.73 | 67.6 | Palliative (P) | 2017-08-05 | 2017-08-16 | CYTARABINE + MITOXANTRONE | N | N | 220036629 | CAPECITABINE |
| 220015000 | 220009632 | 1.63 | null | Palliative (P) | 2014-09-29 | 2014-09-29 | DHAP - R | N | N | 220036632 | CLADRIBINE + CYTARABINE + DAUNORUBICIN |
| 220015001 | 220009634 | 1.62 | 67.5 | Palliative (P) | 2017-02-03 | 2017-04-24 | LENALIDOMIDE | N | N | 220036633 | CAPECITABINE + OXALIPLATIN |
| 220015002 | 220009637 | 1.49 | 55 | Palliative (P) | 2013-04-11 | 2015-10-06 | RAVVA TRIAL | 2 | N | 220036640 | CETUXIMAB + RT |
| 220015003 | 220009639 | 0 | 70.6 | Palliative (P) | 2013-09-22 | 2014-09-25 | BUSULFAN + CYCLO | N | N | 220036641 | RAVVA TRIAL |
| 220015004 | 220009647 | 1.66 | 65 | Palliative (P) | 2017-04-27 | 2017-04-28 | Venetoclax | N | N | 220036653 | CAV |
| 220015005 | 220015095 | 1.56 | 66.8 | Palliative (P) | 2015-01-18 | 2015-03-07 | CISPLATIN + RT | 02 | N | 220036654 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220015006 | 220009650 | 1.64 | 70.5 | Palliative (P) | null | 2017-12-21 | Cyclophosphamide High Dose | 02 | N | 220036659 | IPILIMUMAB |
| 220015007 | 220009651 | 1.32 | null | Palliative (P) | 2017-10-15 | 2017-10-15 | Capecitabine | 99 | N | 220036663 | CVAD |
| 220015009 | 220009654 | 1.72 | 112.7 | Curative (C) | 2016-06-17 | 2016-06-24 | IPILIMUMAB + NIVOLUMAB | 2 | N | 220036669 | EOX |
| 220015010 | 220015097 | 1.65 | 88.65 | null | 2014-02-14 | 2014-02-14 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 220036673 | CLOFARABINE + CYTSARABINE + IDARUBICIN |
| 220015011 | 220015097 | 1.6 | 44.8 | Curative (C) | null | 2018-01-09 | Venetoclax | N | N | 220036673 | IPILIMUMAB + NIVOLUMAB |
| 220015012 | 220009657 | null | 45 | Neo-adjuvant (N) | 2018-01-01 | 2018-01-01 | Bendamustine+Rituximab (1st Course) | null | null | 220036675 | EC |
| 220015013 | 220009658 | 1.73 | 108.5 | Palliative (P) | 2015-03-24 | 2015-05-22 | NIVOLUMAB | N | N | 220036681 | MA |
| 220015014 | 220009659 | 1.72 | 63.9 | Not known (9) | 2015-01-20 | 2015-01-20 | ECarboX | 2 | N | 220036683 | EOX |
| 220015015 | 220009661 | null | 72.5 | Curative (C) | 2015-07-30 | 2015-07-31 | CYTARABINE + MITOXANTRONE | 1 | N | 220036683 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220015016 | 220009661 | 1.78 | 76.6 | Palliative (P) | 2017-10-20 | 2018-01-08 | Gemcitabine 1000mg/m2 D1 8 15 | N | Y | 220036683 | TOPOTECAN |
| 220015017 | 220009662 | 1.9 | 112 | Curative (C) | 2016-06-29 | 2016-06-29 | CHOP R - 21 days | N | N | 220036703 | CISPLATIN + FLUOROURACIL |
| 220015018 | 220009663 | 1.67 | null | Palliative (P) | 2014-03-04 | 2014-03-04 | GEMCITABINE | N | null | 220036716 | FCR |
| 220015019 | 220009664 | 1.59 | 68 | Palliative (P) | 2018-01-30 | 2017-10-17 | PACLITAXEL + TRASTUZUMAB | 01 | N | 220036717 | CISPLATIN + VINORELBINE |
| 220015020 | 220015102 | 1.83 | 73.6 | Palliative (P) | 2018-02-08 | 2018-05-05 | CAPECITABINE + GEMCITABINE | N | N | 220036725 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220015021 | 220015102 | 1.76 | 78.3 | Not known (9) | 2017-11-26 | 2017-11-30 | Temozolomide 150mg/m2 | 02 | N | 220036725 | PEMBROLIZUMAB |
| 220015022 | 220009665 | 1.63 | 52.5 | Palliative (P) | 2016-05-06 | 2016-05-22 | Ipilimumab | N | Y | 220036729 | CISPLATIN |
| 220015023 | 220009666 | 1.8 | null | Palliative (P) | 2017-11-28 | 2017-12-05 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 2 | null | 220036730 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220015024 | 220015103 | 1.77 | 87.1 | Palliative (P) | null | 2015-02-06 | Ipilimumab | N | N | 220036733 | CISPLATIN + METHOTREXATE + VINCRISTINE |
| 220015025 | 220009668 | 1.74 | null | Palliative (P) | 2013-12-06 | 2013-12-06 | BUSULFAN + CYCLO | N | null | 220036733 | IPILIMUMAB |
| 220015027 | 220009672 | 1.71 | 66.8 | Palliative (P) | 2015-01-12 | 2015-01-17 | Sorafenib | 02 | N | 220036742 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220015028 | 220009672 | 1.65 | 65 | Palliative (P) | 2017-08-02 | 2017-08-08 | Irinotecan | N | N | 220036742 | MERCAPTOPURINE + METHOTREXATE |
| 220015029 | 220015106 | 1.6 | null | Palliative (P) | 2012-07-15 | 2013-04-02 | Carboplatin AUC 6 - 10 | 02 | N | 220036755 | CAV |
| 220015030 | 220015107 | 0 | null | Disease modification (D) | 2016-12-13 | 2017-01-13 | MACE | 2 | N | 220036757 | CISPLATIN |
| 220015031 | 220015107 | null | null | Palliative (P) | 2014-12-11 | 2014-12-14 | Abiraterone | N | N | 220036757 | MITOXANTRONE + TRETINOIN |
| 220015032 | 220009676 | null | 18 | Curative (C) | null | 2018-01-03 | BENDAMUSTINE + RITUXIMAB | null | N | 220036760 | FIGARO TRIAL |
| 220015033 | 220009677 | 0 | 106.2 | Curative (C) | 2014-10-21 | 2014-10-30 | Cetuximab 7 day (Cycle 1) | N | N | 220036760 | CISPLATIN + ETOPOSIDE |
| 220015034 | 220009678 | 1.65 | 48 | Not known (9) | 2016-01-08 | 2016-02-05 | Bevacizumab 5mg/kg | N | N | 220000626 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220015035 | 220009679 | 1.75 | 76.8 | Palliative (P) | 2013-08-02 | 2013-08-02 | Erlotinib | N | N | 220000653 | CISPLATIN + FLUOROURACIL |